Nisa Investment Advisors LLC Trims Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Nisa Investment Advisors LLC decreased its position in Amedisys, Inc. (NASDAQ:AMED) by 2.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,970 shares of the health services provider’s stock after selling 300 shares during the period. Nisa Investment Advisors LLC’s holdings in Amedisys were worth $1,445,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC raised its holdings in Amedisys by 41.6% in the 2nd quarter. SG Americas Securities LLC now owns 38,315 shares of the health services provider’s stock valued at $3,517,000 after buying an additional 11,264 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Amedisys by 111.7% in the 1st quarter. BNP Paribas Financial Markets now owns 12,050 shares of the health services provider’s stock worth $1,111,000 after acquiring an additional 6,358 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Amedisys by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider’s stock worth $47,202,000 after acquiring an additional 19,660 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Amedisys by 65.8% during the 1st quarter. California State Teachers Retirement System now owns 54,592 shares of the health services provider’s stock worth $5,031,000 after purchasing an additional 21,671 shares during the period. Finally, Cetera Advisors LLC acquired a new stake in Amedisys in the 1st quarter valued at approximately $1,556,000. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Stock Up 0.9 %

Shares of NASDAQ AMED opened at $95.49 on Monday. The stock has a market cap of $3.13 billion, a P/E ratio of 34.10, a PEG ratio of 1.86 and a beta of 0.78. The business’s fifty day simple moving average is $96.83 and its 200-day simple moving average is $95.66. Amedisys, Inc. has a 12-month low of $89.55 and a 12-month high of $98.95. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Cantor Fitzgerald restated a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft cut Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price for the company. in a report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $100.67.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.